OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Feb 8, 2024 • 22min
S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges related to gender bias that they have faced throughout their careers, growth opportunities that have arisen from these obstacles, and the importance of reflecting on past accomplishments and future goals.
Feb 5, 2024 • 15min
S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment
Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.
Jan 29, 2024 • 17min
S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.
Jan 25, 2024 • 11min
S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL
Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated CLL/SLL; key efficacy and safety data from the BRUIN trial; and guidelines for pirtobrutinib use in clinical practice in the CLL/SLL patient population.
Jan 22, 2024 • 14min
S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management
Dr Lunning sits down with Kami J. Maddocks, MD, of The Ohio State University Comprehensive Cancer Center––James, to discuss the management of MCL in the up-front setting, including practice-changing findings from the SHINE and TRIANGLE trials; how these trial data have altered the role of first-line BTK inhibitors in chemotherapy-free regimens for patients with MCL; and how patient characteristics, such as age and TP53 mutation status affect up-front treatment feasibility.
Jan 15, 2024 • 7min
S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.
Jan 11, 2024 • 22min
S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Drs Monk and Tarantino highlight current research investigating B7-H4–directed ADCs in multiple solid tumor types; other promising ADCs in development for gynecologic cancers; and future research needed to clarify unanswered questions regarding the sequencing of ADCs in breast cancer.
Jan 8, 2024 • 12min
S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new guidance regarding multidisciplinary management.
Jan 4, 2024 • 14min
S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.
Jan 1, 2024 • 16min
S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.
